Pembrolizumab with lenvatinib for untreated PD-L1 positive recurrent or metastatic squamous cell head and neck cancer [ID5118]
Discontinued
Reference number: GID-TA11005
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations, and further details regarding timings and how you can get involved will be available in due course.